Treament News in GIST: EU – Approval for Ripretinib in forth-line

EMAGood news for GIST patients in the EU: In November 2021, the EMA has granted marketing approval for ripretinib (Qinlock®) for patients with advanced gastrointestinal stromal tumours (GIST) who already received three or more kinase inhibitors prior. Read EMA’s press release here:

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.